Crystalline forms of trebrutinib, methods for preparing same, and uses thereof

JP2023553930A5Inactive Publication Date: 2024-11-29GENZYME CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023535327
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-10
Filing Date
2021-11-22
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The amorphous form of trebrutinib (Compound I) exhibits low stability, strong hygroscopicity, and easy decomposition, making it unsuitable for medicinal use.

Method used

A crystalline form of trebrutinib (Form CSI) is developed through systematic experimentation with various processing methods and solvent systems, resulting in improved physicochemical stability, reduced hygroscopicity, and enhanced solubility, hygroscopicity, stability, and bioavailability.

Benefits of technology

Form CSI demonstrates superior stability under various conditions, maintaining chemical purity and preventing impurity formation, thus being suitable for drug development and pharmaceutical use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided are crystalline forms of trebrutinib (hereinafter "Compound I"), methods for preparing the same, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms in the manufacture of BTK inhibitors and drugs for treating multiple sclerosis. The crystalline forms of trebrutinib have one or more improved properties compared to the prior art, making them of great value for future drug optimization and development. [Formula 1] TIFF2023553930000020.tif6597
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of chemical crystallography, and particularly to the crystal forms of trebrutinib, methods for its production, and its uses.

Background Art

[0002] Multiple sclerosis (MS) is a neurological disease affecting more than one million people worldwide. It is the most common cause of neurological disorders in young and middle-aged adults, and has a major physical, psychological, social, and financial impact on the affected individuals and their families. MS involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the central nervous system (CNS). During the course of the disease, sclerosis, i.e., lesions or scars, appear in the myelin sheath of nerve cells, inhibiting the transmission of electrical signals. Sclerosis accumulates over time, leading to the debilitating symptoms experienced by MS patients.

[0003] Immunomodulatory drugs are the mainstay of MS treatment. The results of recent clinical trials have demonstrated the efficacy of drugs targeting B lymphocytes.

[0004] The Bruton's tyrosine kinase (BTK) pathway is important for signal transduction in myeloid cells, including B lymphocytes and CNS microglia. Each of these cell types is involved in the pathophysiology of MS. Furthermore, since BTK signaling is essential for the maturation of B cells into antibody-secreting plasma cells, BTK inhibition may regulate both cellular and humoral immunity. Therefore, inhibitors of BTK signaling represent a dual mechanism targeting both aspects of the immune system.

[0005] Therefore, compounds that inhibit BTK and can both inhibit antigen-induced B cell activation, which is a cause of neuroinflammation, and regulate maladaptive microglial cells associated with neuroinflammation in the brain and spinal cord may be useful for treating relapsing multiple sclerosis (RMS) with advantages over currently available therapies.

[0006] Trebrutinib, an orally selective small molecule BTK inhibitor, has demonstrated safety and efficacy in patients with RMS.

[0007] The chemical name of trebrutinib is (R)-1-(1-acryloylpiperidine-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridine-2(3H)-one (hereinafter referred to as Compound I), and its structure is shown below:

[0008] [ka]

[0009] Crystalline morphology refers to a solid material in which constituent components are arranged in a highly ordered microstructure, forming a crystal lattice that extends in all directions. Polymorphism refers to the phenomenon in which a compound exists in two or more crystalline morphologies. A compound may exist in one or more crystalline morphologies, but their existence and characteristics cannot be reliably predicted. Different crystalline morphologies of a drug substance result in different physicochemical properties, which can affect the in vivo dissolution and absorption of the drug, and to some extent, the clinical efficacy of the drug. In particular, for some poorly soluble oral solid or semi-solid dosage forms, crystalline morphology can be extremely important for the capabilities of the drug product. Furthermore, the physiological and chemical properties of crystalline morphology are very important for the production process. Therefore, polymorphism is an important part of drug research and drug quality control. [Overview of the project] [Problems that the invention aims to solve]

[0010] The white solid form of compound I was disclosed in WO2016196840A1. The inventors of this disclosure repeated the manufacturing process to obtain an amorphous form of compound I. Furthermore, the inventors of this disclosure systematically evaluated the properties of the obtained amorphous form and found that the amorphous form of compound I has drawbacks such as low stability, high hygroscopicity, and easy decomposition, making it unsuitable for pharmaceutical applications. [Means for solving the problem]

[0011] To overcome the shortcomings of the prior art, the inventors of this disclosure conducted systematic studies on compound I and found that compound I readily forms amorphous and is difficult to crystallize. Specifically, the inventors designed numerous experiments involving different processing methods, solvent systems, and post-processing steps to attempt to obtain a solid form of compound I with good physicochemical stability, good hygroscopicity, and low degradability. However, apart from the amorphous form of compound I, a crystalline form suitable for pharmaceutical use could not be obtained. The inventors of this disclosure tried many more methods and, surprisingly, obtained a crystalline form of compound I. This crystalline form has advantages in at least one aspect of solubility, hygroscopicity, purification ability, stability, viscosity, compressibility, fluidity, in vitro and in vivo dissolution, and bioavailability. In particular, the crystalline form of compound I of this disclosure has advantages such as good stability, good hygroscopicity, and low degradability, which solves the problems present in the prior art and is of great significance for the development of drugs containing compound I.

[0012] This disclosure provides a novel crystalline form of compound I, a method for producing the same, and its use.

[0013] For the purposes of this disclosure, the crystalline form of compound I is provided.

[0014] Furthermore, the crystal morphology CSI of compound I is provided (hereinafter referred to as morphology CSI).

[0015] In one embodiment presented herein, the X-ray powder diffraction pattern of morphological CSI includes one, two, or three characteristic peaks at two-theta values ​​of 7.7°±0.2°, 11.0°±0.2°, and 22.8°±0.2°, using CuKα radiation. Preferably, the X-ray powder diffraction pattern of morphological CSI includes characteristic peaks at two-theta values ​​of 7.7°±0.2°, 11.0°±0.2°, and 22.8°±0.2°, using CuKα radiation.

[0016] In another embodiment presented herein, the X-ray powder diffraction pattern of morphological CSI includes one, two, or three characteristic peaks at two-theta values ​​of 12.0°±0.2°, 16.1°±0.2°, and 18.5°±0.2° using CuKα radiation. Preferably, the X-ray powder diffraction pattern of morphological CSI includes characteristic peaks at two-theta values ​​of 12.0°±0.2°, 16.1°±0.2°, and 18.5°±0.2° using CuKα radiation.

[0017] In another embodiment presented herein, the X-ray powder diffraction pattern of morphological CSI includes one, two, or three characteristic peaks at two-theta values ​​of 13.6°±0.2°, 20.1°±0.2°, and 24.8°±0.2°, using CuKα radiation. Preferably, the X-ray powder diffraction pattern of morphological CSI includes characteristic peaks at two-theta values ​​of 13.6°±0.2°, 20.1°±0.2°, and 24.8°±0.2°, using CuKα radiation.

[0018] In another embodiment presented herein, the X-ray powder diffraction pattern of morphology CSI, using CuKα radiation, includes one, two, three, four, five, six, seven, eight, or nine characteristic peaks at 2-theta values ​​of 7.7°±0.2°, 11.0°±0.2°, 22.8°±0.2°, 12.0°±0.2°, 16.1°±0.2°, 18.5°±0.2°, 13.6°±0.2°, 20.1°±0.2°, 24.8°±0.2°, and 18.7°±0.2°.

[0019] While not intended to imply any limitations, the X-ray powder diffraction pattern of morphological CSI is substantially as shown in Figure 2, using CuKα radiation.

[0020] While not intended to imply any limitations, the DSC curve for morphological CSI is essentially as depicted in Figure 6, showing an endothermic peak around 170°C (start temperature). This peak is the fusion endothermic peak.

[0021] Although it is not meant to be limiting in any way, the TGA curve of Form CSI is substantially as depicted in Figure 5 and shows a weight loss of about 0.4% when heated from 31 °C to 160 °C.

[0022] Although it is not meant to be limiting in any way, Form CSI is an anhydride.

[0023] For the purposes of the present disclosure, a method for manufacturing Form CSI is also provided. The method comprises: adding a solid of Compound I to a ketone or an ether, stirring at a constant temperature, and separating to obtain Form CSI.

[0024] Furthermore, the ketone is preferably a C3-C6 ketone and the ether is preferably a C5 ether.

[0025] Furthermore, the ketone is preferably 4-methyl-2-pentanone and the ether is preferably methyl tert-butyl ether.

[0026] Furthermore, the stirring temperature is preferably from room temperature to 55 °C and the stirring time is preferably more than 25 hours.

[0027] For the purposes of the present disclosure, the present disclosure provides the use of Form CSI for manufacturing other crystalline forms or salts of Compound I.

[0028] For the purposes of the present disclosure, a pharmaceutical composition is provided, which comprises a therapeutically effective amount of a crystalline form of Compound I and a pharmaceutically acceptable excipient.

[0029] Furthermore, the use of a crystalline form of Compound I according to the present disclosure for the manufacture of a BTK inhibitor is provided.

[0030] Furthermore, the use of a crystalline form of Compound I according to the present disclosure for the manufacture of a medicament for the treatment of multiple sclerosis is provided.

[0031] Furthermore, the crystalline form of compound I is preferably morphological CSI.

[0032] Technical issues resolved by this disclosure The inventors of this disclosure studied the prior art and found that the prior art is amorphous compound I. Through their research, they found that amorphous compound I has drawbacks such as low chemical stability, low hygroscopicity, and susceptibility to decomposition, making it unsuitable for pharmaceutical applications and industrial production. To overcome the shortcomings of the prior art, this disclosure provides a crystalline form of compound I that has excellent physical and chemical stability, good hygroscopicity, and is suitable for the development of drugs containing compound I.

[0033] As shown in Example 1, compound I is difficult to crystallize. Only amorphous forms were obtained by various crystallization methods. Even after trying different crystallization methods and controlling the processing conditions of the manufacturing process, such as solvents (alcohols, ketones, esters, ethers, acids, water, nitriles, amides, halogenated hydrocarbons, aromatic hydrocarbons, alkanes, sulfoxides, etc.), temperature, time, evaporation rate, additives, and other factors, only amorphous forms were obtained. To obtain the morphological CSI of this disclosure, the inventors further tried various unconventional solvents and improved the manufacturing and post-processing conditions based on the previous manufacturing methods. This demonstrates that the morphological CSI provided by this disclosure is unpredictable to those skilled in the art.

[0034] Technical effects The form of CSI disclosed herein has the following unexpected advantages: (1) The chemical purity of the prior art solid decreases significantly when stored under conditions of 25°C / 60%RH, 40°C / 75%RH, 60°C / 75%RH, and 80°C. In particular, after 6 months of storage in open packaging at 40°C / 75%RH, the purity decreases by 3.46%, and the number of impurities exceeding the qualified threshold increases to four. After 1 month of storage in sealed packaging at 60°C / 75%RH, the purity decreases by 2.76%, and the number of impurities exceeding the qualified threshold increases to two. After 1 month of storage in open packaging at 60°C / 75%RH, the purity decreases by more than 6.3%, and the number of impurities exceeding the qualified threshold increases to four. The chemical stability of the prior art solid falls far below pharmaceutical standards.

[0035] Compared to the prior art, the morphological CSI APIs of the present disclosure exhibit good stability both in themselves and in drug products. The crystalline state of the morphological CSI API remains unchanged for at least 6 months when stored in open and sealed packaging under conditions of 25°C / 60%RH. The chemical purity is greater than 99.8% and remains substantially unchanged during storage. After mixing the morphological CSI with excipients to form a drug product and storing it under conditions of 25°C / 60%RH, the crystalline state of the morphological CSI drug product remains unchanged for at least 3 months. These results demonstrate that the morphological CSI APIs of the present disclosure exhibit good stability under long-term conditions, both in themselves and in drug products, and are suitable for drug storage.

[0036] On the other hand, the crystalline state of the morphological CSI API remains unchanged for at least 6 months when stored in open and sealed packaging under conditions of 40°C / 75%RH. The crystalline state of the morphological CSI API remains unchanged for at least 1 month when stored in open or sealed packaging under conditions of 60°C / 75%RH. The chemical purity is above 99.8% and remains substantially unchanged during storage. The chemical purity of the morphological CSI API remains substantially unchanged for at least 2 days when stored under conditions of 80°C. After mixing the morphological CSI with excipients to form a drug product and storing it under conditions of 40°C / 75%RH, the crystalline state of the morphological CSI drug product remains unchanged for at least 3 months. These results indicate that the morphological CSI API has better stability under accelerated and stressed conditions, both in itself and in drug products. The API and drug products will be subjected to high temperature and humidity conditions caused by seasonal, regional climate, and environmental differences during storage, transportation, and manufacturing. Therefore, good stability under accelerated and stress conditions is crucial for drug development. Morphologically crystalline synthetic (CSI) active pharmaceutical ingredients exhibit good stability under stress conditions, both in themselves and in drug products, which is beneficial in avoiding the impact on drug quality due to crystal transformation or purity degradation during drug storage.

[0037] Furthermore, the impurity content of the morphological CSI active pharmaceutical ingredient did not exceed the qualification threshold throughout the stability testing process, thus meeting the requirements for drug development.

[0038] (2) Compared with the prior art, the morphological CSI of the present disclosure has good hygroscopicity. Test results show that the weight increase of the morphological CSI is only 1 / 7 of that of the prior art. The weight increase of the morphological CSI at 80% RH is 0.53%, indicating that the morphological CSI is slightly hygroscopic. The weight increase of the prior art solid at 80% RH is 3.69%, indicating that the prior art is hygroscopic.

[0039] In one embodiment, low hygroscopicity makes chemical decomposition and polymorphism more likely, which directly affects the physical and chemical stability of the active pharmaceutical ingredient.

[0040] Furthermore, low hygroscopicity reduces the fluidity of the active pharmaceutical ingredient (API), which in turn affects its processing.

[0041] In another aspect, low hygroscopic active pharmaceutical ingredients require a low-humidity environment during production and storage, imposing stringent production requirements and increasing costs. More importantly, low hygroscopicity can lead to variability in the content of the active pharmaceutical ingredient in the drug product, consequently affecting the quality of the drug product.

[0042] The form of CSI provided by this disclosure, having good hygroscopic properties, is not subject to stringent production and storage conditions, reduces production, storage, and quality control costs, and has strong economic value. [Brief explanation of the drawing]

[0043] [Figure 1] This figure shows the XRPD pattern of sample 1 according to Example 1. [Figure 2] This figure shows the XRPD pattern of the morphological CSI according to Example 2. [Figure 3] This figure shows the XRPD pattern of the morphological CSI according to Example 3. [Figure 4] This figure shows the XRPD pattern of the morphological CSI according to Example 4. [Figure 5] This figure shows the TGA curve for morphological CSI. [Figure 6] This figure shows the DSC curve of morphological CSI. [Figure 7] This figure shows XRPD pattern overlays of the morphology CSI before and after storage (from top to bottom: initial, stored for 6 months at 25°C / 60%RH (open packaging), stored for 6 months at 25°C / 60%RH (sealed packaging), stored for 6 months at 40°C / 75%RH (open packaging), stored for 6 months at 40°C / 75%RH (sealed packaging), stored for 1 month at 60°C / 75%RH (open packaging), and stored for 1 month at 60°C / 75%RH (sealed packaging)). [Figure 8] This figure shows the DVS plot of morphological CSI. [Figure 9]This figure shows the DVS plot of the prior art amorphous material. [Figure 10] This figure shows XRPD pattern overlays of morphological CSI before and after the compounding process (from top to bottom: excipient, after compounding process, and morphological CSI). [Figure 11] This figure shows XRPD pattern overlays of morphological CSI drug products stored under different conditions (top to bottom: initial drug product, stored at 25°C / 60%RH for 3 months, stored at 40°C / 75%RH for 3 months). [Modes for carrying out the invention]

[0044] This disclosure is further illustrated by the following examples which describe in detail the manufacture and use of the crystalline forms of this disclosure. It will be apparent to those skilled in the art that modifications of materials and methods can be achieved without departing from the scope of this disclosure.

[0045] The abbreviations used in this disclosure are explained below: XRPD: X-ray Powder Diffraction DSC: Differential Scanning Calorimetry TGA: Thermogravimetric analysis DVS: Dynamic Vapor Solubilization 1 1H NMR: Proton Nuclear Magnetic Resonance RH: Relative humidity UPLC: Ultra-high-performance liquid chromatography LC: Liquid Chromatography PE: Polyethylene LDPE: Low-density polyethylene HDPE: High-density polyethylene

[0046] Equipment and methods used for data collection: The X-ray powder diffraction patterns in this disclosure were obtained using a Bruker X-ray powder diffractometer. The parameters of the X-ray powder diffraction method in this disclosure are as follows: X-ray: Cu, Kα Kα1(Å):1.54060;Kα2(Å):1.54439 Kα2 / Kα1 intensity ratio: 0.50

[0047] The thermogravimetric analysis (TGA) data in this disclosure were obtained using TA Q500. The parameters of the TGA method in this disclosure are as follows: Heating rate: 10℃ / min Purge gas: Nitrogen

[0048] The differential scanning calorimetry (DSC) data in this disclosure were acquired using a TA Q2000. The parameters of the DSC method in this disclosure are as follows: Heating rate: 10℃ / min Purge gas: Nitrogen

[0049] Dynamic vapor sorption (DVS) was measured using SMS (Surface Measurement Systems Ltd.) proprietary DVS equipment. Typical parameters for the DVS test are as follows: Temperature: 25℃ Gas and flow rate: Nitrogen, 200 mL / min RH range: 0%RH to 95%RH

[0050] Proton nuclear magnetic resonance spectral data ( 1 ¹H NMR spectra were collected using a Bruker Avance II DMX 400M Hz NMR spectrometer. 1–5 mg of the sample was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to obtain solutions with concentrations of 2–10 mg / mL.

[0051] The relevant substances in this disclosure were detected by UPLC, and the parameters are shown below.

[0052] [Table 1]

[0053] In this disclosure, the “stirring” is achieved using conventional methods in the art, such as magnetic stirring or mechanical stirring, and the stirring speed is 50 to 1800 r / min.

[0054] Preferably, the magnetic stirring speed is 300 to 900 r / min, and the mechanical stirring speed is 100 to 300 r / min.

[0055] The aforementioned "separation" is achieved using conventional methods in the field, such as centrifugation or filtration. The "centrifugation" procedure is as follows: the sample to be separated is placed in a centrifuge tube, and then centrifuged at a rate of 10,000 r / min until all the solid has settled to the bottom of the tube.

[0056] The aforementioned "drying" is achieved using conventional methods in the art, such as vacuum drying, forced-air drying, or free-air drying. The drying temperature may be above room temperature. Preferably, the drying temperature is room temperature to about 60°C, or room temperature to about 50°C, or room temperature to about 40°C. The drying time may be 2 to 48 hours, or overnight. Drying is achieved in a ventilated hood, a forced-air convection oven, or a vacuum oven.

[0057] The aforementioned "room temperature" is not a specific temperature, but rather a temperature within the range of 10 to 30°C.

[0058] The aforementioned "open packaging" involves placing the sample in a glass vial, covering the vial with aluminum foil, and making 5 to 10 holes in the foil.

[0059] The aforementioned "sealed packaging" involves placing the sample in a glass vial, tightly sealing the vial, and then sealing the vial in an aluminum foil bag.

[0060] The aforementioned "characteristic peak" refers to a representative diffraction peak used to distinguish crystals, and using CuKα radiation, it may generally have a deviation of ±0.2°.

[0061] In this disclosure, “crystal” or “crystal morphology” refers to a crystal or crystal morphology identified by the X-ray diffraction patterns shown herein. Those skilled in the art will understand that experimental errors depend on instrument conditions, sample preparation, and sample purity. The relative intensities of diffraction peaks in an X-ray diffraction pattern may also vary depending on experimental conditions; therefore, the order of diffraction peak intensities cannot be considered the sole or decisive factor. In fact, the relative intensities of diffraction peaks in an X-ray powder diffraction pattern are related to the preferred orientation of the crystal, and the diffraction peak intensities shown herein are illustrative; identical diffraction peak intensities are not required. Therefore, those skilled in the art will understand that the crystal morphologies in this disclosure do not necessarily have to have X-ray diffraction patterns identical to the examples shown herein. Any crystal morphology having identical or similar characteristic peaks in its X-ray diffraction pattern should be included in the scope of this disclosure. Those skilled in the art can compare the patterns shown herein with those of unknown crystal morphologies to determine whether these two sets of patterns reflect the same or different crystal morphologies.

[0062] In some embodiments, the form CSI of the Disclosure is pure and substantially free of any other crystalline form. In the Disclosure, when the term “substantially free” is used to describe a novel crystalline form, it means that the content of other crystalline forms in the novel crystalline form is less than 20% (w / w), specifically less than 10% (w / w), more specifically less than 5% (w / w), and even more specifically less than 1% (w / w).

[0063] In this disclosure, the term “approximately” means, when referring to measurable values ​​such as weight, time, and temperature, to include variations of ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified quantity.

[0064] Unless otherwise specified, the following examples were performed at room temperature.

[0065] According to this disclosure, compound I and / or its salt used as a raw material is in solid (crystalline or amorphous), oily, liquid, or solution form. Preferably, compound I used as a raw material is solid.

[0066] The raw materials for compound I and / or its salts used in the following examples were prepared by known methods of the prior art, for example, the method disclosed in WO2016196840A1. [Examples]

[0067] Attempts to produce Compound I in solid form The inventors of this disclosure experimented with various methods to produce the solid form, adjusting various processing conditions, such as solvents (alcohols, ketones, esters, ethers, acids, water, nitriles, amides, halogenated hydrocarbons, aromatic hydrocarbons, alkanes, sulfoxides, etc.), temperature, time, evaporation rate, additives, and other factors. More than 100 experiments were conducted, but only amorphous materials were obtained. Some of the experimental methods and results are described in Tables 2-6.

[0068] [Table 2]

[0069] Method 1: Stirring According to Table 3, a fixed mass of compound I solid was weighed into a glass vial, and then a fixed volume of solvent was added. After stirring at a fixed temperature for a fixed time, the solid was separated. All obtained solids were confirmed to be amorphous by XRPD. The XRPD pattern of sample 1 is substantially as shown in Figure 1.

[0070] [Table 3]

[0071] Method 2: Evaporation According to Table 4, a fixed mass of compound I solid was weighed into a glass vial. After adding a fixed volume of solvent and additives, the system was evaporated at room temperature. All obtained solids were confirmed to be amorphous by XRPD.

[0072] [Table 4]

[0073] Method 3: Solid vapor diffusion According to Table 5, a fixed mass of compound I solid was weighed into a glass vial. The vial was placed into a larger glass vial containing approximately 5 mL of the corresponding solvent. The larger glass vial was sealed with a lid and placed at a constant temperature to ensure sufficient contact between the solvent atmosphere and the solid in the vial. After one day, all solids were removed for XRPD testing and confirmed to be amorphous.

[0074] [Table 5]

[0075] Method 4: Liquid vapor diffusion According to Table 6, a fixed mass of compound I solid was weighed into a glass vial and dissolved in a fixed volume of solvent. The vial was placed into a larger glass vial containing approximately 5 mL of the corresponding reverse solvent, and the larger glass vial was then sealed with a lid and placed at a constant temperature to allow sufficient diffusion of the reverse solvent vapor into the inner vial. All solids were isolated and, after diffusion for different time periods, were confirmed to be amorphous by XRPD.

[0076] [Table 6]

[0077] The experimental results described above indicate that compound I is difficult to crystallize and that amorphous forms are easily obtained. The inventors of this disclosure further experimented with various unconventional solvents, as described in Examples 2-4, and improved the manufacturing and post-processing conditions, ultimately obtaining the crystalline form of compound I unexpectedly. [Examples]

[0078] Method of manufacturing morphological CSI 300.8 mg of compound I solid was weighed into a 3 mL glass vial, and then 2.0 mL of methyl isobutyl ketone was added. After stirring at 50°C for approximately 39 hours, the solid was isolated. The obtained solid was confirmed to be the morphological CSI of the present disclosure. The XRPD pattern is substantially as depicted in Figure 2, and the XRPD data is listed in Table 7.

[0079] [Table 7-1] [Table 7-2] [Examples]

[0080] Method of manufacturing morphological CSI 300.1 mg of compound I solid was weighed into a 3 mL glass vial, and then 2.0 mL of methyl isobutyl ketone was added. After stirring at 50°C for approximately 6 days, the solid was isolated. The obtained solid was confirmed to be morphological CSI of the present disclosure by XRPD. The XRPD pattern is substantially as shown in Figure 3, and the XRPD data is listed in Table 8.

[0081] [Table 8-1] [Table 8-2] [Examples]

[0082] Manufacturing of Morphological CSI 300.4 mg of compound I solid was weighed into a glass vial, and then 3.0 mL of methyl tert-butyl ether was added. After stirring at 50°C for approximately 68 hours, the solid was isolated. After vacuum drying at 75°C for 1 hour, the obtained solid was confirmed to be the morphological CSI of the present disclosure, and the XRPD data are shown in Figure 4 and Table 9.

[0083] The TGA curve is essentially as shown in Figure 5, showing a weight loss of approximately 0.4% when heated from 31°C to 160°C.

[0084] The DSC curve is essentially as shown in Figure 6. It shows a single endothermic peak around 170°C (start temperature), which is the fusion endothermic peak of morphological CSI.

[0085] 1 The 1H NMR data is as follows: 1 HNMR (400MHz, DMSO) δ (ppm) 7.75 (d, 1H), 7.52-7.36 (m, 4H), 7.21 (t, 1H), 7.14 (t, J=7.8Hz, 4H), 6.98 (d, 1H), 6.91-6.76(m, 1H), 6.13(dd, J=16.5, 7.0Hz, 1H), 5.69(dd, J=16.7, 10.8Hz, 1H), 4.82(s, 2H), 4.50 (t, J=14.3Hz, 1H), 4.15 (dd, J=33.9, 12.5Hz, 2H), 3.76 (t, J=13.0Hz, 0.5H), 3.16 (t, J=12.7Hz, 0.5H), 2.79-2.61 (m, 0.5H), 2.45-2.29 (m, J=13.0, 9.1Hz, 1H), 2.10-1.74 (m, 2H), 1.66-1.37 (m, 1H). (According to the structure of compound I, a peak of one piperidine hydrogen appears at δ3.33-3.76 ppm. Half of this hydrogen is spitted and obscured by the water signal because it is close to the water peak.)

[0086] [Table 9] [Examples]

[0087] Physical and chemical stability of morphological CSI Certain amounts of the morphological CSI of this disclosure and the prior art amorphous material were weighed and stored under conditions of 25°C / 60%RH, 40°C / 75%RH, and 60°C / 75%RH, respectively. Purity and solid morphology were determined by ULC and XRPD. The results are shown in Table 10, and XRPD overlays of the morphological CSI before and after stability evaluation are shown in Figure 7.

[0088] [Table 10]

[0089] The dosage of compound I is 60 mg once daily.

[0090] The results showed that morphological CSI was stable for at least 6 months under 25°C / 60%RH and 40°C / 75%RH conditions, with its solid form and purity remaining essentially unchanged, demonstrating that morphological CSI has good stability under both long-term and accelerated conditions. After storage for 1 month under 60°C / 75%RH conditions, the solid form and purity remained essentially unchanged, demonstrating that morphological CSI has good stability even under stress conditions. The impurity content of the morphological CSI API did not exceed the qualification threshold throughout the stability investigation process, meeting the requirements for drug development. After storage at 25°C / 60%RH, 40°C / 75%RH, and 60°C / 75%RH, the purity of the prior art amorphous material decreased significantly, falling far below the requirements for drug development. After storage in open packaging at 40°C / 75%RH for 6 months, the purity decreased by 3.46%, and the number of impurities exceeding the qualification threshold increased to 4. After storage in sealed packaging at 60°C / 75%RH for only one month, the purity decreased by 2.76%, and the number of impurities exceeding the qualification threshold increased to two. After storage in open packaging at 60°C / 75%RH for only one month, the purity decreased by more than 6.3%, and the number of impurities exceeding the qualification threshold increased to four. The results demonstrate that the morphological CSI of this disclosure has outstanding chemical stability when compared to prior art amorphous materials. [Examples]

[0091] Stability of morphological CSI at high temperatures Approximately 10 mg each of the morphological CSI and prior art amorphous materials of this disclosure were stored at 80°C for 2 days, and the initial and final purities were determined by UPLC as shown in Table 11.

[0092] [Table 11]

[0093] The results show that the chemical purity of morphological CSI remains essentially unchanged for two days at 80°C, whereas significant decomposition of amorphous material is observed under the same conditions. Morphological CSI of this disclosure exhibits superior stability at high temperatures compared to prior art amorphous material. [Examples]

[0094] Moisture absorption of morphological CSI Certain amounts of the morphological CSI and prior art amorphous materials of this disclosure were sampled for hygroscopicity testing using a dynamic vapor sorption (DVS) instrument. Weight changes at each relative humidity were recorded during cycles from 0%RH to 95%RH to 0%RH at 25°C, and the experimental results are shown in Table 12. The DVS plots for morphological CSI and amorphous materials are shown in Figures 8 and 9, respectively.

[0095] [Table 12]

[0096] The results show that morphological CSI is slightly hygroscopic, with a weight increase of 0.53% at 80% RH, while the prior art solid is hygroscopic, with a weight increase of 3.69% at 80% RH. The hygroscopicity of morphological CSI is superior to that of the prior art.

[0097] Explanation and definition of hygroscopicity (Chinese Pharmacopoeia 2020 General Notice 9103 Guidelines for Drug Hygroscopicity Testing, experimental conditions: 25±1℃, 80±2%RH): Deliquescent: It absorbs enough water and becomes a liquid. Extremely high hygroscopicity: Mass increase of 15.0 percent or more. Hygroscopicity: Mass increase is less than 15.0 percent and greater than or equal to 2.0 percent. Slight hygroscopicity: Mass increase is less than 2.0 percent and greater than or equal to 0.2 percent. Non-hygroscopic or nearly non-hygroscopic: Mass increase is less than 0.2 percent. (The definition of hygroscopicity in the 10th edition of the European Pharmacopoeia, section 5.11, is similar to that of the Chinese Pharmacopoeia.) [Examples]

[0098] Manufacturing of morphological CSI drug products A drug product was prepared using an appropriate amount of the morph CSI of the present disclosure according to the formulations and processes shown in Tables 13 and 14. XRPD was tested before and after formulation. The XRPD overlay is shown in Figure 10, demonstrating that the morph CSI of the present disclosure is physically stable before and after the formulation process.

[0099] [Table 13]

[0100] [Table 14] [Examples]

[0101] Stability of morphological CSI drug products To evaluate the stability of morphological CSI in the drug product, the packaged drug product prepared in Example 8 was stored for 3 months under conditions of 25°C / 60%RH and 40°C / 75%RH. The XRPD overlays of the drug product before and after storage are shown in Figure 11.

[0102] The results indicate that the drug product in morphological CSI is stable for at least 3 months under conditions of 25°C / 60%RH and 40°C / 75%RH.

[0103] The embodiments described above are for illustrative purposes only to illustrate the technical concepts and configurations of the Disclosure and are intended to enable those skilled in the art to understand and implement the Disclosure, and should not be used to conclude that they limit the scope of protection of the Disclosure. Any equivalent variations or modifications in accordance with the spirit of the Disclosure should be included within the scope of protection of the Disclosure.

Claims

1. Compound I 【Chemistry 1】 A crystalline form of The X-ray powder diffraction pattern contains characteristic peaks at 2-theta values ​​of 7.7°±0.2°, 11.0°±0.2°, 22.8°±0.2°, 12.0°±0.2°, 16.1°±0.2°, and 18.5°±0.2°, using CuKα radiation, a crystalline form of Compound I.

2. 2. The crystalline form of Compound I of claim 1, wherein the X-ray powder diffraction pattern contains at least one characteristic peak at 2-theta values ​​of 13.6°±0.2°, 20.1°±0.2°, and 24.8°±0.2° using CuKα radiation.

3. 2. The crystalline form of Compound I of claim 1, having an X-ray powder diffraction pattern as depicted in FIG. 2 using CuKα radiation.

4. 13. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of claim 1 and a pharma- ceutically acceptable excipient.